August 31, 2021 7:56am
Futures are like playing whack-a-ball
Pre-open indications: BUYs: 3; Maintain SELL: 2
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Never leave an investor uninformed!
Dow futures are DOWN -0.03% (-9 points), S&P futures are DOWN -0.02% (-1 point) and NASDAQ futures are UP +0.05% (+7 points)
Stock futures were mixed, fluctuating and weakening on Tuesday as record highs had reigned,
European stocks opened slightly higher with economic data showing euro zone economic sentiment eased more than expected in August, from a record high in July,
Asia-Pacific shares slipped after China’s factory activity grew at a slower pace in August as compared with the previous month, data released Tuesday showed.
Tuesday marks the last trading day of August.
The S&P 500 is up 3% this month, while the Nasdaq has climbed 4%, on pace to post its third winning month in a row, while the Dow is up 1.3%.
Although the stem, cell and gene therapy sector dived on Monday.
Data Docket: Investors are awaiting a key jobs report on Friday ahead of the Labor Day weekend.
If you didn’t know what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Monday’s evening’s recap: the cell and gene therapy sector’s upside collapsed as the session progressed. Why have we dismissed share pricing risk as record highs reign?” … https://www.regmedinvestors.com/articles/12072
- The Nasdaq closed UP +136.39 points (+0.90%);
- The IBB closed up +0.10% and XBI closed down -0.30%;
- Sector volume was LOW with 3 of the 7-upside having higher than the 3-month average volume with very LOW volume of 4 of 26-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.20 points or -1.22% at 16.19;
- Monday’s percentage (%) of the 7-upside were +0.13% (VCEL) to +24.59% (BSTG) while the 26-downside -0.04% (SAGE) to -5.69% (EDIT);
- August - 11 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?
Biostage (BSTG) closed up again +$0.75 to $3.80 with 25,607 shares traded after Friday’s +$0.45 to $3.05 with 19,982 share traded, Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded and last Tuesday’s +$0.28 with 10,590 shares traded and the previous Monday’s +$0.68 to $1.89 with 38,354 shares traded.
Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?
Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? WHERE is the SEC?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
bluebird bio (BLUE) closed down -$0.28 after Friday’s +$0.20 and Thursday’s down -$0.28 and has a positive +$0.14 or +0.78% pre-market indication,
Cellectis SA (CLLS) closed down -$0.32 and has a positive +$0.67 or +4.80% pre-market indication,
Intellia Therapeutics (NTLA) closed down -$6.05 with a positive =$0.84 or +0.55% pre-market indication,
Maintaining SELL into Strength:
Vericel (VCEL) closed up again +$0.07 after Friday’s +$2.98 to $55.61, chart looks peaky and there was a +$0.52 or +0.93% aftermarket indication – make some profit with a +250.85% 52-week change,
The BOTTOM LINE: One day left in the month that is all but over; a Labor Day holiday is on the horizon and I am prepared for a slow week and time-off – shoveling mulch and revamping the garage.
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.